Business

Boehringer Ingelheim has announced that the Spiriva Respimat tiotropium soft mist inhaler is now available in the United States. Patients will also still be able to purchase Spiriva Handihaler, the company said. The FDA approved… Read more . . .

NovaBiotics, which has plans to develop an inhaled version of its Lynovex cysteamine (NM001) for the treatment of cystic fibrosis, has announced that it has raised £5 million in a private placement from Woodford Investment… Read more . . .

Aradigm Corporation announced that it has received patents for its Pulmaquin inhaled ciprofloxacin from the European and Australian patent offices. The European patent (EU Patent No. 2,079,443) is titled “Dual Action, Inhaled Formulations Providing Both… Read more . . .

Egalet Corporation, which is developing several treatments for chronic pain, has announced the acquisition of Sprix ketorolac tromethamine nasal spray from Daiichi Sankyo subsidiary Luitpold Pharmaceuticals for $7 million. Ketorolac is a non-steroidal anti-inflammatory drug… Read more . . .

Vectura has announced that it will partner with Janssen Biotech to develop inhaled dry powder anti-inflammatory products for the treatment of asthma and COPD. Janssen’s drug candidates will be developed using Vectura’s DPI delivery technology,… Read more . . .

Novartis has reportedly sued Cipla in the Delhi High Court for infringing patents related to Novartis’s Onbrez Breezhaler indacaterol DPI (Arcapta Neohaler). Cipla began marketing a generic indacaterol DPI called “Unibrez” in October; after losing… Read more . . .

Lightlake Therapeutics has agreed to license its intranasal naloxone for opioid overdose reversal to Adapt Pharma for possible development and sales milestones of more than $55 million, plus royalties, the company said. Lightlake recently announced… Read more . . .